How to Think Clearly About Pharmacological Prospecting

By: Tiago Santana - Founder & CEO, Gray Group International • Serial entrepreneur and growth strategist who has built and scaled multiple companies across technology, media, and consulting. Expert in growth strategist and editorial voice for a global think tank building companies that advance the human experience

Key takeaways

• Start with a thorough assessment of your specific requirements before choosing a solution.
• Compare multiple options and verify that each meets your documented criteria.
• Avoid over- or under-investing: the right fit balances cost, performance, and long-term value.

Pharmacological prospecting is the disciplined search for drug candidates from chemical or biological sources. The real value comes from system design, not from hit count alone. Teams win when they link source quality, assay quality, ADME/Tox filters, IP, supply, and access rights from day one.

In This Article:

• Key takeaways
• Pharmacological prospecting is more than finding hits
• Why great science is not enough
• Why speed matters less than portfolio design
• Why sourcing is a strategic issue
• What actually holds up in practice
• Sources and further reading

Pharmacological prospecting is more than finding hits

In short: Pharmacological prospecting is closer to portfolio construction than treasure hunting.

Pharmacological prospecting is closer to portfolio construction than treasure hunting. The common mistake is to treat hit discovery as the finish line. In practice, a hit only starts the expensive part. Each later step removes weak assets, so a weak program can look productive for a long time before it collapses.

That is why stage-gate thinking helps. Ask five questions in order: is the signal real, can chemistry improve it, will exposure be adequate, can safety be managed, and can supply scale? If one gate fails, value leaks out fast. Industry cost and timeline estimates vary, but they all point in the same direction: early discipline saves money later.

How do chemical libraries create early value?

Chemical libraries create value when they improve learning speed per dollar spent. Many libraries are biased toward easy-to-make compounds rather than biologically rich ones. By comparison, DNA-encoded libraries can test huge numbers of binders cheaply against purified targets. That is useful in target-based programs, but binding is not the same as function.

A common mistake is confusing screen scale with decision quality. Library strategy works best when it matches mechanism risk. If target confidence is high, a focused library around known chemotypes may beat a giant blind screen. If target confidence is low, phenotypic screening may produce fewer hits but better disease relevance.

Why do natural products still matter?

Natural products still matter because biology has already done part of the chemistry search for us. Many drugs trace back to natural scaffolds or natural product logic. Antibiotics, anticancer agents, and immunosuppressants show that evolved chemistry still teaches medicinal chemists new tricks.

That said, natural-product programs fail when teams skip dereplication or provenance controls. Dereplication means identifying known compounds early so you do not spend months re-isolating old chemistry. Metadata quality often matters as much as extraction quality. Ethnopharmacological leads can help prioritize where to look, but only if consent and benefit-sharing are sound.

Why great science is not enough

In short: Great science without translation discipline often creates elegant dead ends.

Great science without translation discipline often creates elegant dead ends. A program may show strong potency, then fall apart on exposure, off-target risk, or manufacturability. Many early teams focus more on novelty than on attrition mechanics, but that is backwards if capital efficiency matters.

A useful lens is simple: good science must survive supplier power, buyer pressure, and substitution risk. Supplier power shows up as dependence on rare source material. Buyer power appears later through payer pressure and standard-of-care comparisons. Threat of substitutes includes existing therapies with cleaner safety profiles.

Can target validation reduce costly attrition?

Yes, but only if validation goes beyond expression data or pathway stories. A target should show human relevance through genetics, patient samples, perturbation studies, or strong disease models. Many teams overrate targets because the mechanism sounds neat on slides. On closer inspection, validation lowers one kind of risk while leaving others untouched.

A genetically supported target may still be hard to drug selectively. In practice, target validation should guide how much money you spend before broad screening begins. It should also connect to a translational marker, so later work can show whether the biology changes in a real system.

Why do safety and manufacturability matter early?

Because late fixes are expensive and often impossible. HERG liability can flag heart rhythm risk early. CYP interactions can predict drug-drug problems before animals or humans see the compound. ADME/Tox triage should sit close to hit confirmation, not months later.

Manufacturing also starts earlier than most founders expect. If your active depends on scarce biomass or a long synthetic route with poor yield, your margin structure may break before Phase II data arrives. Early safety and manufacturing checks prevent teams from overinvesting in assets that cannot become practical medicines.

Why speed matters less than portfolio design

In short: Speed matters less than many decks claim.

Speed matters less than many decks claim. Fast iteration helps only when each cycle improves signal quality. Otherwise, you just learn the wrong things faster. R&D spending in pharma and biotech is large, which is one reason productivity pressure is so intense. Yet high-throughput activity alone does not solve portfolio math.

Use an expansion lens here. Existing modality plus known target is the lower-risk path. New modality plus new biology creates multiple risks at once: scientific risk, manufacturing risk, regulatory risk, and financing risk. Portfolio design beats raw speed because compounding risks destroy value faster than cycle time can recover it.

How do screened libraries shape risk?

Screened libraries shape what kinds of failures you will see later. Broad diversity libraries may improve novelty but also raise follow-up burden and false positives. Focused libraries reduce noise but may trap you near crowded IP zones. Fragment screens offer cleaner starting points for medicinal chemistry, but they need stronger structural biology support later.

Library choice also shapes partnering options. Buyers care about freedom to operate as much as potency charts. If a library creates easy hits but weak rights, the program may look strong in a lab and weak in diligence. That tradeoff should be part of planning, not a surprise at deal time.

Where do partnerships destroy or preserve value?

Partnerships preserve value when each side owns a distinct bottleneck well, such as source access, assay systems, chemistry, disease biology insight, or the development path. They destroy value when incentives split across too many handoffs without shared data rules or kill criteria. Weak governance turns collaboration into delay.

Before signing, ask who owns improvements from shared material, who bears ABS compliance duties, and who controls negative data. If those answers are vague now, disputes will get expensive later. Good partnerships remove bottlenecks and clarify rights early; bad ones hide future conflict inside today's excitement.

Why sourcing is a strategic issue

In short: Sourcing changes cost structure, timeline reliability, reputation risk, and IP defensibility.

Sourcing changes cost structure, timeline reliability, reputation risk, and IP defensibility. Legal compliance is only one part of the operating problem. A common mistake is assuming sample possession equals commercial freedom to operate. It does not in many jurisdictions.

Sourcing choices affect the whole chain of evidence: consent records, permits, specimen metadata, chain of custody, and data governance. Community expectations around use and returns also matter. Miss those basics and even good science can become unusable in diligence.

How do biodiversity rules affect bioprospecting?

They affect who can collect, study, export, patent, and commercialize materials derived from biodiversity-linked resources in participating jurisdictions. Rules vary by country, so timelines can differ sharply across geographies. Synthetic library prospecting avoids some field-access complexity, but it also loses biodiversity-linked differentiation that many investors want in a natural-product story.

Consider a firm choosing between marine samples from multiple countries and microbial collections with clear provenance records already in hand. The second path may move slower scientifically at first but faster commercially later. Biodiversity rules influence where you source, how fast you move, and what rights you can defend later.

Why protect indigenous knowledge and data rights?

Traditional knowledge can direct search effort toward bioactive organisms more efficiently than random sampling, but using that knowledge without consent repeats extractive models. Respect here is not charity. It is operating discipline and legitimacy protection.

Frameworks around genetic resources, traditional knowledge, and disclosure issues exist because ownership boundaries remain contested across markets. Leaders should treat benefit sharing, attribution, consent scope, downstream data use, and publication rights as first-order design choices. They are not cleanup work after discovery success arrives.

What actually holds up in practice

In short: What holds up is boringly consistent: clear source rights, reproducible assays, fast dereplication, early ADME/Tox, plausible CMC paths, and tight stop-go rules tied to evidence rather than optimism.

What holds up is boringly consistent: clear source rights, reproducible assays, fast dereplication, early ADME/Tox, plausible CMC paths, and tight stop-go rules tied to evidence rather than optimism. Strong programs use an evidence stack model. Each asset must earn progress across biological truth, chemical tractability, safety margin, supply path, and rights clarity.

If one stack stays weak for too long, do not rescue it with storytelling. Kill it or redesign it quickly. The best prospecting engines are not the ones with the loudest results. They are the ones that can eliminate weak ideas cheaply and move stronger ones forward with confidence.

How should leaders assess a prospecting program?

Use a short diligence scorecard. Score each program on source integrity, assay validity, dereplication plan, ADME/Tox timing, translational biomarkers, IP room, manufacturing path, ABS compliance, and partner incentives. Then compare the weighted total against budget needs.

Weakness clustered in one domain often predicts future delays better than average scores do. If a team cannot explain its kill criteria in plain English within five minutes, it is probably under-governed. The best question is not "Can this discover something?" It is "Can this become medicine under real-world constraints?".

Ready to turn insight into action?

Gray Group International works with business leaders to turn insight into action. Reading about the right approach is one thing; building the team, processes, and decisions that actually move metrics inside your specific organization is another. That second part is where most of the value lives, and it's where we focus.

Every engagement starts with a working session, not a deck. We listen to where you are today, look at the data and constraints with you, and propose the next two or three concrete moves that we believe will produce the most leverage. You leave with a plan you can act on whether or not you continue to work with us.

Let's Connect

Sources and further reading

• United Nations - sustainability and global development